Retrospective study pairs semaglutide with dapagliflozin in diabetic kidney disease

The wire

1. 01Chart review of 126 patients with type 2 diabetes and chronic kidney disease, 42 per group, compared semaglutide, dapagliflozin and the combination over eight weeks of treatment.
2. 02Combination therapy showed larger reductions in fasting and postprandial glucose, HbA1c, blood urea nitrogen, creatinine, 24-hour urinary protein, ESR, IL-6 and hs-CRP, with no rise in recorded adverse events.
3. 03Authors caution the design was retrospective with non-random treatment assignment, modest sample size and only eight weeks of follow-up, so long-term renal benefit is not established.

From the source

Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease

Medicine · 2026 Oct 9 · Gong C, Luo Q, Li Q et al.